Literature DB >> 26501848

Perspectives on Cost and Value in Cancer Care.

Leonard B Saltz1.   

Abstract

Mesh:

Substances:

Year:  2016        PMID: 26501848     DOI: 10.1001/jamaoncol.2015.4191

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  17 in total

1.  Assessing the financial toxicity in Tunisian cancer patients using the Comprehensive Score for Financial Toxicity (COST).

Authors:  Nesrine Mejri; Yosra Berrazega; Ryma Boujnah; Haifa Rachdi; Houda El Benna; Soumaya Labidi; Hamouda Boussen
Journal:  Support Care Cancer       Date:  2021-01-06       Impact factor: 3.603

2.  Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature.

Authors:  Phyllis Ocran Mattila; Rabbiya Ahmad; Syed Shahzad Hasan; Zaheer-Ud-Din Babar
Journal:  Front Public Health       Date:  2021-04-30

3.  Early Accountable Care Organization Results in End-of-Life Spending Among Cancer Patients.

Authors:  Miranda B Lam; Jie Zheng; E John Orav; Ashish K Jha
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

Review 4.  The high price of anticancer drugs: origins, implications, barriers, solutions.

Authors:  Vinay Prasad; Kevin De Jesús; Sham Mailankody
Journal:  Nat Rev Clin Oncol       Date:  2017-03-14       Impact factor: 66.675

5.  Spending outcomes among patients with cancer in accountable care organizations 4 years after implementation.

Authors:  Parsa Erfani; Jessica Phelan; E John Orav; Jose F Figueroa; Ashish K Jha; Miranda B Lam
Journal:  Cancer       Date:  2021-11-12       Impact factor: 6.860

Review 6.  Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

Authors:  Leonard B Saltz
Journal:  Cancer J       Date:  2016 May-Jun       Impact factor: 3.360

7.  Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.

Authors:  Guoqiang Liu; Shuo Kang; Xinchen Wang; Fangjian Shang
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

8.  Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer.

Authors:  Pedro Nazareth Aguiar; Carmélia Maria Noia Barreto; Bárbara de Souza Gutierres; Hakaru Tadokoro; Gilberto de Lima Lopes
Journal:  Einstein (Sao Paulo)       Date:  2017 Jul-Sep

Review 9.  State of play and clinical prospects of antibody gene transfer.

Authors:  Kevin Hollevoet; Paul J Declerck
Journal:  J Transl Med       Date:  2017-06-07       Impact factor: 5.531

Review 10.  Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies.

Authors:  Gianfranco Mattia; Rossella Puglisi; Barbara Ascione; Walter Malorni; Alessandra Carè; Paola Matarrese
Journal:  Cell Death Dis       Date:  2018-01-25       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.